- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
Sucralfat is only minimally absorbed from the GI-tract [SmPC].
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Reflux oesophagitis, prophylaxis of stress ulcers and recurrent ulcers |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
Adjustment in renal impairment as specified:
GFR 50-80 ml/min/1.73 m2
Dose adjustment not neededGFR 30-50 ml/min/1.73 m2
Dose adjustment not neededGFR 10-30 ml/min/1.73 m2
Avoid long-term use because of the risk of encephalopathy from accumulation of absorbed aluminum.GFR < 10 ml/min/1.73 m2
A general recommendation is not providedA second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Bezoar formation has been reported in newborns after sucralfate administration. In premature neonates, aluminium accumulation in the bones was observed [SmPC].
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| H2-receptor antagonists | ||
|---|---|---|
| A02BA01 | ||
| A02BA03 | ||
| A02BA02 | ||
| Proton pump inhibitors | ||
|---|---|---|
| A02BC05 | ||
| A02BC01 | ||
| A02BC02 | ||
| Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) | ||
|---|---|---|
| A02BX13 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
- Daschner, M, Tabellarium Nephrologicum, Dosierungs- und Therapieschemata bei pädiatrischer Niereninsuffizienz, 3. Auflage, Shaker Verlag, Aachen, 2009
- Genericon, SmPC Sucralfat Genericon 1 g/5 ml orale Susp. (1-20571), 03/2018
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
